UK markets close in 6 hours 12 minutes

Sinopharm Group Co. Ltd. (X2S.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
2.2580+0.0260 (+1.16%)
As of 08:01AM CET. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 7.15B
Enterprise value 15.20B
Trailing P/E 6.67
Forward P/E 6.36
PEG ratio (5-yr expected) 50.46
Price/sales (ttm)0.10
Price/book (mrq)0.83
Enterprise value/revenue 0.03
Enterprise value/EBITDA 0.61

Trading information

Stock price history

Beta (5Y monthly) 0.72
52-week change 37.63%
S&P500 52-week change 3-9.23%
52-week high 32.5600
52-week low 31.8880
50-day moving average 32.3298
200-day moving average 32.1929

Share statistics

Avg vol (3-month) 32.85k
Avg vol (10-day) 31.62k
Shares outstanding 51.34B
Implied shares outstanding 6N/A
Float 81.34B
% held by insiders 10.01%
% held by institutions 151.07%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.11
Forward annual dividend yield 44.93%
Trailing annual dividend rate 30.75
Trailing annual dividend yield 333.60%
5-year average dividend yield 43.30
Payout ratio 429.56%
Dividend date 3N/A
Ex-dividend date 427 Jun 2022
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in CNY.

Fiscal year

Fiscal year ends 31 Dec 2021
Most-recent quarter (mrq)30 Sept 2022

Profitability

Profit margin 1.45%
Operating margin (ttm)3.93%

Management effectiveness

Return on assets (ttm)3.64%
Return on equity (ttm)13.19%

Income statement

Revenue (ttm)546.15B
Revenue per share (ttm)175.01
Quarterly revenue growth (yoy)9.60%
Gross profit (ttm)44.05B
EBITDA 23.5B
Net income avi to common (ttm)7.91B
Diluted EPS (ttm)0.3400
Quarterly earnings growth (yoy)2.10%

Balance sheet

Total cash (mrq)38.21B
Total cash per share (mrq)12.24
Total debt (mrq)76B
Total debt/equity (mrq)71.58
Current ratio (mrq)1.31
Book value per share (mrq)21.01

Cash flow statement

Operating cash flow (ttm)8.51B
Levered free cash flow (ttm)10.05B